$16.09
+0.83 (+5.44%)
Open$15.15
Previous Close$15.26
Day High$17.72
Day Low$15.00
52W High$71.50
52W Low$7.76
Volume—
Avg Volume1.71M
Market Cap1.45B
P/E Ratio—
EPS$-4.39
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
+8.8% upside
Current
$16.09
$16.09
Target
$17.51
$17.51
$11.65
$17.51 avg
$27.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 33.92M | 91.01M | 366.27M |
| Net Income | -299,653,025 | -723,605,372 | 43.81M |
| Profit Margin | -883.4% | -839.2% | 12.0% |
| EBITDA | -214,714,214 | -547,299,445 | 53.48M |
| Free Cash Flow | — | — | 19.66M |
| Rev Growth | -62.7% | -62.7% | -4.9% |
| Debt/Equity | 2.39 | 2.39 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |